Cephalalgia 1996: Vol 16 Index

47 Pages·1996·10.9 MB·English

Cephalalgia
International
Journal
ofH eadache
VOLUME 16
Cephalalgia
Founding Editor, Ottar Sjaastad; Editor-in-Chief, K. M. A. Welch, USA; Assistant Editors, Howard Feit, Nabih Ramadan and Gretchen
Tietjen, USA; European Editors, Lars Edvinsson, Sweden and Marcia Wilkinson, UK; Book Review Editor, Anne MacGregor, UK;
Historical Section Editor, Hansruedi Isler, Switzerland.
EDITORIAL BOARD
Frank Andrasik, USA Fabio Facchinetti, Italy Martin Lauritzen, Denmark Birthe K. Rasmussen, Denmark
Michael Anthony, Australia Marcello Fanciullacci, Italy Tony J. F. Lee, USA F. Clifford Rose, England
Otto Appenzeller, USA M. D. Ferrari, Netherlands Richard B. Lipton, USA David Russell, Norway
Bo Bille, Sweden Lars Friberg, USA Ninan Mathew, USA Fumihiko Sakai, Japan
J. N. Blau, England Marek J. Gawel, Canada James McCulloch, Scotland Merton Sandler, England
Nikolai Bogduk, Australia Vivette Glover, UK Kathleen Ries Merikangas, USA Pramod R. Saxena, Netherlands
Marie-Germaine Bousser, France P. J. Goadsby, Australia/London Harold Merskey, Canada Jean Schoenen, Belgium
Naomi Breslau, USA Hartmut Gobel, Germany Michael A. Moskowitz, USA Federigo Sicuteri, Italy
G. W. Bruyn, Netherlands Steven R. Graff-Radford, USA G. Nappi, Italy Stephen D. Silberstein, USA
Gennaro Bussone, Italy Vincenzo Guidetti, Italy Giovanni Nattero, Italy Ottar Sjaastad, Norway
Gabriela Buzzi, Italy Jan Hardebo, Sweden Jes Olesen, Denmark D. Soyka, Germany
Desmond Carroll, England A. Murray Harper, Scotland John Pearce, UK Egilius L. H. Spierings, USA
Giovanni D’Andrea, Italy P. Henry, France Stephen J. Peroutka, USA Felia Titus, Spain
Jackie de Belleroche, UK Rachel Hering, Israel V. Pfaffenrath, Germany Walter Stewart, USA
Milena De Marinis, Italy Judith Hockaday, England Alison J. Pilgrim, UK Kazuro Takahashi, Japan
S. I. Dexter, England Hisaka Igarashi, Japan A. Pradalier, France Peer Tfelt-Hansen, Denmark
H. C. Diener, Germany Lee Kudrow, USA A. Prusinski, Poland N. Vijayan, USA
Peter Drummond, Australia Ashraf Kurdi, Jordan Edgard Raffaelli, Jr., Brazil Maurice Vincent, Brazil
John Edmeads, Canada Arieh Kuritzky, Israel Alan M. Rapoport, USA Elisabet Waldenlind, Sweden
Karl Ekbom, Sweden James W. Lance, Australia Neil Hugh Raskin, USA Dewey Ziegler, USA
Bjorn Ellertsen, Norway
Cephalalgia is included in the ADONIS service. Accordingly, copies of individual articles are available on compact discs (CD-ROM) and can be
printed out on demand. An explanatory leaflet is available from the publisher.
Information about journals and books from Scandinavian University Press is available on our homepage on the world wide web,
URL-address http://www.scup.no
PROGRAMME Cephalalgia is published eight times per year and contains original papers on all aspects of headache. The journal
provides an international forum for original research papers, review articles, and short communications. Hypotheses may also be
published. Supplements are supplied free of charge to the subscribers and copies can be purchased on application to the publisher.
Contributions appearing in this journal are abstracted and indexed in Biological Abstracts, Biotechnology Citation Index, Chemical Abstracts
(1981-1983), Current Advances in Ecological and Environmental Sciences, Current Contents/Clinical Medicine, Current Contents/Life Sciences
(1993-), Excerpta Medica/EMBASE, FaxonFinder, Index Medicus (1981-)/MEDLINE, Index to Dental Literature, INIS Atomindex, Medical
Documentation Service, National Epilepsy Library and Resource Center, Neuroepidemiology, Neuroscience Citation Index, Nutrition Research
Newsletter, Psychological Abstracts/Psyc INFO (1993-), Nuclear Medicine Literature, Research Alert, Science Citation Index (1993-), SciSearch.
MANUSCRIPT ADDRESSES Contributors are requested to send four copies of their manuscripts to: Editor-in-chief of Cephalalgia,
K. M. A. Welch, Henry Ford Hospital and Health Science Center, Department of Neurology, 2799 W. Grand Blvd., Detroit, MI 48202,
USA. Fax: [phone]. Book Review manuscripts should be sent to Anne MacGregor, City of London Migraine Clinic,
22 Charterhouse Square, London EC1M 6DxX, UK.
BUSINESS ADDRESS Communications concerning publishing and subscription matters (copyright, requests for permissions, reprints,
advertising, subscriptions, distribution, back issues, manuscripts, proofs and orders for offprints, etc.) should be addressed to the
publisher: Scandinavian University Press, Journals Division, PO Box 2959 Teyen, 0608 Oslo, Norway (Tel: [phone], Fax:
[phone], E-mail: [email protected]). Customers in the US and Canada are invited to address the North American Office
as follows: Scandinavian University Press North America, 875 Massachusetts Avenue, Ste. 84, Cambridge, MA 02139, USA (Tel:
[phone], Fax: [phone]. Toll-free telephone: [phone]). Email [email protected].
SUBSCRIPTION PRICE One volume (eight issues)—Institutions USD 255.00. IHS members USD 115.00. Nordic countries: Institutions
NOK 1530.00. Airmailed to subscribers worldwide. In Japan, all subscriptions should be ordered through the Maruzen Co. Ltd.,
3-10 Nihonbashi 2-Chome, Chuo-ku, Tokyo 103, Japan. This journal can be ordered in microform from University Microfilms
International, 300 N. Zeeb Rd., Dept. P.R., Ann Arbor, MI 48106, USA.
Cephalalgia (ISSN 0333-1024) is published eight times per year by Scandinavian University Press, P.O. Box 2959 Tayen, 0608 Oslo,
Norway. Periodical postage paid at Jamaica, NY 11431, USA. Postmasters: Send address changes to Scandinavian University Press
North America. Air freight and mailing in the USA by Publications Expediting Inc.
© 1996 International Headache Society. All rights reserved; no part of the publication Cephalalgia may be reproduced, stored in a retrieval system, or transmitted in
any form or by any means; electronic, mechanical, photocopying, recording or otherwise without prior written permission from Scandinavian University Press as
agent for International Headache Society.
Special regulation for photocopies in the USA: Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is
granted by Scandinavian University Press for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service,
provided the fee of US$9.00 per article is paid to CCC, 27 Congress Street, Salem MA 01970, USA. 0333-1024/96/US$9.00. This authorization does not include
copying for general distribution, promotion, new works, or resale. In these cases, specific written permission must be obtained from Scandinavian University Press.
Typeset and printed in the UK by H. Charlesworth Ltd., Huddersfield.
Cephalalgia 1996;16. Oslo. ISSN 0333-1024
Subject index
3,4-dihydroxyphenylacetic acid In vitro pharmacology of electriptan (UK-116,044) a
Cerebrospinal fluid tyrosine and potent partial agonist at the ’SHT-1D-like” receptor in
3,4-dihydroxyphenylacetic acid levels in migraine the dog saphenous vein, 386
patients, 56 Preclinical in vivo pharmacology of electriptan
311C90 (Zolmitriptan) (UK-116,044): a potent and selective partial agonist at
311C90 (Zolmitriptan), a novel centrally and peripheral the ’5HT 1D-like” receptor, 386
acting oral 5-hydroxytryptamine-1D agonist: a The aborption potential of electriptan (UK-116,044) and
comparison of its absorption during a migraine attack sumatriptan, 387
and in a migraine-free period, 270 A dose-finding study of eletriptan (UK-116,044)
311C90 and sumatripan produce indistinguishable (5-30 mg) for the acute treatment of migraine, 387
CNS adverse event profiles, 389 Minimal interaction between 311C90, a novel
The combination of 311C90, a novel antimigraine antimigraine compound, and oral pizotifen, 395
compound, and oral propranolol in healthy subjects, Gender and region difference in side-effects induced
395 by sumatriptan, 396
Minimal interaction between 311C90, a novel The high efficacy of 311C90 in treating migraine
antimigraine compound, and oral pizotifen, 395 headaches is maintained in patients using oral
The high efficacy of 311C90 in treating migraine contraceptives, 396
headaches is maintained in patients using oral Chest pain and sumatriptan: a disagreeable sensation
contraceptives, 396 or a witness for the prosecution, 397
311C90 has no clinically significant effects on blood 311C90 has no clinically significant effects on blood
pressure, 398 pressure, 398
Confirmation of the long-term efficacy of 311C90 in the Confirmation of the long-term efficacy of 311C90 in the
acute oral treatment of migraine, 399 acute oral treatment of migraine, 399
Confirmation of the long-term safety and efficacy of Confirmation of the long-term safety and efficacy of
oral 311C90 in the acute treatment of migraine: oral 311C90 in the acute treatment of migraine:
demographic analysis from a study > 20,000 treated demographic analysis from a study > 20,000 treated
attacks, 400 attacks, 400
Oral 311C90 is effective in treatment of menstrual Chest symptoms after sumatripan: a two year clinical
migraine, 400 practice review in 735 consecutive migraine patients,
5HT agents 554
Sumatriptan: vasoactive effect on human dural vessels, abdominal migraine
demonstrated by subselective angiography, 224 Is bowel permeability a measure of abdominal
Autoradiographic distribution of [3H] sumatriptan- migraine in children?, 355
binding sites in post-mortem human brain, 317 Is abdominal migraine often environmentally
Serotonin syndrome complicating migraine determined?, 378
pharmacotherapy, 323 acetazolamide
Zolmitriptan inhibits c-fos expression in the dorsal Acetazolamide as a confirmatory diagnostic test for
horn of the medulla and upper cervical horn evoked migraine headaches, 362
by sagittal sinus stimulation in the cat, 355 adhesion molecules
Is response to oral sumatriptan in childhood migraine CAM (cell adhesion molecules)-based nitrergic
different from adults, 358 mechanisms in experimental migraine, 356
Dose-finding studies of rizatriptan (MK-462) in the agraphia
acute treatment of migraine, 359 Agraphia as the only symptom of a migraine aura, 562
The effects of low doses of BMS-180048 compared with alexithymia
placebo in acute migraine, 360 Migraine and alexithymia: a Rorschach study, 383
A comparison of oral eletriptan (UK-116,044) alniditan
(20-80 mg) and oral sumatriptan (100 mg) in the acute Alniditan in the acute treatment of migraine attacks: a
treatment of migraine, 368 subcutaneous dose-finding study, 497
Confirmation of the long-term safety of 311090 in the arteriovenous malformation
acute oral treatment of migraine, 372 Cluster headache syndrome associated with middle
Efficacy of sumatriptan 50 mg/os in the migraine cerebral artery arteriovenous malformation, 202
attack. Open study on 50 patients, 383 autonomic nervous system
Post-marketing clinical use- and misuse- of Autonomic nervous system function in migraineurs
sumatriptan in migraine patients: state of the art, 384 during headache-free period: a blood pressure and
Can sumatriptan be anxiogenic migraineurs, 384 heart rate variability study, 388
The use of sumatriptan in patients with concomitant Peripheral autonomic potentials in primary headache,
epilepsy and migraine, 385 390
The safety, tolerability and pharmacokinetics of Autonomic nervous system and neuroendocrine
intravenous electriptan (UK-116,044), a new potent changes in patients with idiopathic trigeminal
and selective ’5HT 1D-line” receptor agonist, 385 neuralgia, 476
iv Subject index CEPHALALGIA 16 (1996)
blood vessels The International Headache Society classification of
Reactions of the middle meningeal artery of the cat to chronic daily and near-daily headaches: a critique of
neural and humoral stimulation, 27 the criticism, 407
Sumatriptan: vasoactive effect on human dural vessels, chronic tension-type headache
demonstrated by subselective angiography, 224 Exteroceptive suppression of temporal muscle activity
Calcitonin gene-related peptide is released from is normal in chronic tension-type headache and not
capsaicin-sensitive nerve fibres and induces related to actual headache state, 251
vasodilation of human cerebral arteries concimitant chronic paroxysmal hemicrania
with activation of adenylyl cyclase, 310 Neuropeptide changes in a case of chronic paroxysmal
Intracerebral arteries and gadolinium enhancement in hemicrannia-evidence for trigemino-parasympathetic
migraine without aura, 363 activation, 448
Stimulation of cranial vessels excites neurones in the classification—controversy
medial thalamus of the cat, 365 Migraine and tension-type headache are separate
Histamine induces relaxation of the human cerebral disorders, 217
artery by activation of endothelial H1-receptors Migraine and tension-type headache are not separate
coupled to nitric oxide synthase, 374 disorders, 220
Innervation of the human middle meningeal artery: Are the International Headache Society criteria for
immunohistochemistry, ultrastructure and headache useful?, 289
vasomotility, 374 The International Headache Society classification and
A novel non-peptide ETA/B receptor antagonist, SB diagnostic criteria are valid and extremely useful, 293
209670, inhibits trigeminal nerve induced effects in the The International Headache Society classification: to
carotid vascular bed, 379 use or not to use?, 295
Relationships between cortical spreading depression classification
and the parasympathetic cerebrovascular innervation, IHS criteria and gender: a study on migraine and
394 tension-type headache in children and adolesents, 107
Evaluation of non-invasive techniques to assess A nosographic analysis of the migraine aura in a
vasoconstriction in healthy volunteers using general population, 380
methoxamine as a probe drug, 507 Migrainous disorder and its relation to migraine
BMS-180048 without aura and migraine with aura, 431
The effects of low doses of BMS-180048 compared with The International Headache Society classification of
placebo in acute migraine, 360 chronic daily and near-daily headaches: a critique of
c-fiber the criticism, 407
Sympathectomy induces C-fiber sprouting and mast cluster headache
cell activation in rat dura mater, 370 Pain pressure threshold in cluster headache patients,
calcitonin gene-related peptide 62
Calcitonin gene-related peptide is released from IV histamine therapy in intractable cluster headaches,
capsaicin-sensitive nerve fibres and induces 357
vasodilation of human cerebral arteries concimitant Study of indole metabolism in cluster headche
with activation of adenylyl cyclase, 310 sufferers, 358
H a-CGRP in the middle meningeal and temporal The m-chlorophenylpiperazine test in cluster headache:
arteries of man: binding by autoradiography and a study on central serotoninergic activity, 358
vasomotor responses in vitro, 373 Regional cerebral blood flow in patients with cluster
cannabis headache during cluster period. A single photon
An epidemiological study on the activity of cannabis emission tomography (SPET) study using Tc 99M
in idiopathic headache, 377 HMPAO, 365
cerebral blood flow ’“Continuous” cluster like headache with response to
Regional cerebral blood flow in patients with cluster sumatriptan and steroids, 392
headache during cluster period. A single photon cluster headache—clinical
emission tomography (SPET) study using Tc 99M Cluster headache syndrome associated with middle
HMPAO, 365 cerebral artery arteriovenous malformation, 202
cerebrospinal fluid pressure Spectral analysis of heart rate fluctuations in cluster
Primary low cerebrospinal fluid pressure syndrome headache, 357
with galactorrhea: findings at MR imaging, 124 Natural history of cluster headache, 390
chest pain Sluder’s syndrome and cluster headache, 391
Chest pain and sumatriptan: a disagreeable sensation Premonitory symptoms and precipitating (triggering)
or a witness for the prosecution, 397 factors in cluster headache (CH), 391
chronic daily headache cluster headache—genetics
Demographic and clinical characteristics of patients Familial cluster headache, 391
with episodic migraine versus chronic daily headache, cluster headache—treatment
44 Melatonin vs. placebo in the prophyalxis of cluster
Psychiatric consultation of patients with chronic daily headache: a double-blind pilot study with parallel
headache in Turkey, 393 groups, 494
CEPHALALGIA 16 (1996) Subject index Vv
controversy Pain control in migraine attacks: results from a double-
The primary headache disorders—apple sauce or fruit blind, randomized, within-patient, placebo-controlled
cocktail?, 223 trial comparing diclofenac-K and ergotamine +
corticosteroids caffeine, 359
”Continuous” cluster like headache with response to Effects of ergotamine on myocardial blood flow—a pet
sumatriptan and steroids, 392 study, 373
CSF estradiol
Cerebrospinal fluid tyrosine and Distinct properties of signal transduction in patients
3,4-dihydroxyphenylacetic acid levels in migraine with migraine, menstrual migraine, postmenopausal
patients, 56 headache and effects of estradiol treatment, 356
CT scan event-related potential
CT scan in headache patients in an outpatient clinic, Predictability of a migraine attack? An event-related
390 potential study, 363
cyclandelate evoked potentials
Cyclandelate in the prophylaxis of migraine: a Pattern reversal visual evoked potentials in children
randomized, parallel, double-blind study in with migraine or tension-type headache, 104
comparison with placebo and propranolol, 441 exterocetive suppression
depression Exteroceptive suppression of temporal muscle activity
Hyperprolactinemia and depression induced by is normal in chronic tension-type headache and not
oxetorone, 560 related to actual headache state, 251
dihydroergotamine facial ecchymosis
Migraine prophylaxis with slow-release Recurrent paroxysmal headache associated with facial
dihydroergotamine, 398 ecchymosis, 341
drug-induced headache factor V
Amitryptyline and dexamethasone combined treatment Point mutation (Arg506-Gln) of factor V in migraine
in drug-induced headache, 197 with and without aura. A pilot study, 394
Serotonin receptor plasticity in patients with analgesic- familial hemiplegic migraine
induced headache, 374 Familial hemiplegic migraine: a clinical comparison of
Long-term outcome of patients with headache and families linked and unlinked to chromosome 19, 153
drug abuse after inpatient withdrawal: five-year Stroke as first episode of familial hemiplegic migraine,
follow-up, 481 379
electriptan (UK-116,044) Classification problems in familial hemiplegic
The safety, tolerability and pharmacokinetics of oral migraine, 384
eletriptan (UK-116,044) a potent and selective 5HT1D- fenfluramine induced headache
like receptor agonist, 368 Fenfluramine induced headache: characteristics and
A comparison of oral eletriptan (UK-116,044) biochemistry, 364
(20-80 mg) and oral sumatriptan (100 mg) in the acute fibromyalgia
treatment of migraine, 368 Fibromyalgia (alias central panalgia): the severest
Preclinical in vivo pharmacology of electriptan expression of dysnociception, 366
(UK-116,044): a potent and selective partial agonist at flunarizine
the “5HT 1D-like’’ receptor, 386 Post-marketing cohort study comparing the safety and
The pharmacokinetics of eletriptan (UK-116,044) in rats efficacy of flunarizine and propranolol in the
and dogs, 387 prophylaxis of migraine, 328
The aborption potential of electriptan (UK-116,044) and Long-term follow-up after flunarizine or nimodipine
sumatriptan, 387 discontinuation in migraine patients, 337
A dose-finding study of eletriptan (UK-116,044) Freud
(5-30 mg) for the acute treatment of migraine, 387 Freud and migraine: the beginning of a
electromyographic—biofeedback psychodynamically oriented view of headache a
Electromyographic-biofeedback (EMG-BFB) efficacy to hundred years go, 22
treatment of juvenile tension type headache: results at gabapentin
2 years follow-up, 388 Gabapentin in migraine prophylaxis, 367
epidemiology gliadin sensitivity
An epidemiological study on the activity of cannabis Screening of gliadin sensitivity in children suffering
in idiopathic headache, 377 from migraine, 393
An epidemiologic study of headache among children glyceryl trinitrate
and adolescents, 545 Glyceryl trinitrate produces prolonged changes in
epilepsy cortical nitric oxide release in the anaesthetized cat,
Occipital paroxysms in children with migraine and 379
epilepsy, 364 head trauma
The use of sumatriptan in patients with concomitant Migraine associated with head trauma, 375
epilepsy and migraine, 385 headache
ergotamine An epidemiological study on the activity of cannabis
Side effects of ergotamine, 5 in idiopathic headache, 377
vi Subject index CEPHALALGIA 16 (1996)
headache—clinical idiopathic stabbing headache
A quality of life instrument for adolescents with Idiopathic stabbing headache (jabs and jolts
chronic headache, 183 syndrome), 93
Differential sensitivity to morphine challenge in induced headache
migraine sufferers and headache-exempt subjects, 297 Serotonin receptor adaptation in patients with
Recurrent paroxysmal headache associated with facial analgesic induced headache, 419
ecchymosis, 341 Platelet serotonin in patients with analgesic induced
CT scan in headache patients in an outpatient clinic, headache, 423
390 ketamine
headache—historical Relief of migraine attack with N-methyl-D-aspartic
Freud and migraine: the beginning of a acid receptor antagonist ketamine: a double-blind
psychodynamically oriented view of headache a comparison with placebo-theoretic implications, 372
hundred years go, 22 m-chlorophenylpiperazine
Headache as an occupational illness in the treatise ‘De The m-chlorophenylpiperazine test in cluster headache:
morbis artificum diatriba” of Bernardino Ramazzini, a study on central serotoninergic activity, 358
87 magnesium
A 6th Century Irish headache cure and its use in a Prophylaxis of migraine with oral magnesium; results
South Germany monastery, 536 from a prospective, multi-center, placebo-controlled
headache—epidemiology and double-blind randomized study, 257
Electrominographical ischemic test symptom
Epidemiological study of headache in childhood, 401
evaluation and intra and extracellular magnesium
headache—pathogenesis
Peripheral autonomic potentials in primary headache, concentration in headache patients, 402
Magnesium in the prophylaxis of migraine—double-
390
blind placebo controlled study, 436
Electrominographical ischemic test symptom
magnetic resonance imaging
evaluation and intra and extracellular magnesium
Brain MRI in children with migraine, 541
concentration in headache patients, 402
mast cell
headache—pediatric
Sympathectomy induces C-fiber sprouting and mast
Pattern reversal visual evoked potentials in children
cell activation in rat dura mater, 370
with migraine or tension-type headache, 104
melatonin
IHS criteria and gender: a study on migraine and
Melatonin vs. placebo in the prophyalxis of cluster
tension-type headache in children and adolesents,
headache: a double-blind pilot study with parallel
107
groups, 494
Recurrent ophthalmoplegia in childhood: diagnostic
menstrual migraine
and etiologic considerations, 276
“Menstrual” migraine: towards a definition, 11
Is bowel permeability a measure of abdominal
Distinct properties of signal transduction in patients
migraine in children?, 355
with migraine, menstrual migraine, postmenopausal
Occipital paroxysms in children with migraine and
headache and effects of estradiol treatment, 356
epilepsy, 364
Oral 311C90 is effective in treatment of menstrual
The results of two studies on the behaviorial treatment
migraine, 400
of young headache patients, 367
Platelet serotonin pathway in menstrual migraine, 427
Brain MRI in children with migraine, 541 Variations in the platelet arginine/nitric oxide
An epidemiologic study of headache among children pathway during the ovarian cycle in females affected
and adolescents, 545
by menstrual migraine, 468
headache—therapy methoxamine
Ketoprofen, paracetamol and placebo in the treatment Evaluation of non-invasive techniques to assess
of episodic tension-type headache, 117 vasoconstriction in healthy volunteers using
hemicrania methoxamine as a probe drug, 507
Hemicrania with trigeminal neuralgia, 380 middle meningeal artery
histamine Reactions of the middle meningeal artery of the cat to
IV histamine therapy in intractable cluster headaches, neural and humoral stimulation, 27
357 migraine
Histamine induces relaxation of the human cerebral The primary headache disorders—apple sauce or fruit
artery by activation of endothelial H1-receptors cocktail?, 223
coupled to nitric oxide synthase, 374 migraine—clinical
Histamine inhalation is a specific but insensitive Menstrual” migraine: towards a definition, 11
laboratory test for migraine, 550 Demographic and clinical characteristics of patients
hyperprolactinemia with episodic migraine versus chronic daily headache,
Hyperprolactinemia and depression induced by 44
oxetorone, 560 Pattern reversal visual evoked potentials in children
hypertension headache with migraine or tension-type headache, 104
Simultaneous therapeutic intervention in patients with IHS criteria and gender: a study on migraine and
headache and arterial hypertension, 382 tension-type headache in children and adolesents, 107
CEPHALALGIA 16 (1996) Subject index vii
Should we investigate migraine of late onset?, 201 Red wine-induced release of “CJ5-hydroxytryptamine
Migraine and tension-type headache are separate from platelets of migraine patients and controls, 41
disorders, 217 Cerebrospinal fluid tyrosine and
Migraine and tension-type headache are not separate 3,4-dihydroxyphenylacetic acid levels in migraine
disorders, 220 patients, 56
Distinct properties of signal transduction in patients Inhalational anesthetics inhibit spreading depression:
with migraine, menstrual migraine, postmenopausal relevance to migraine, 87
headache and effects of estradiol treatment, 356 Regional cerebral blood flow (rCBF) in migraine
Migraine without aura and migaine with aura are during the interictal period: different rCBF patterns in
distinct clinical entities; a study of 484 male and patients with and without aura, 161
female migraineurs from the general population, 361 Zolmitriptan inhibits c-fos expression in the dorsal
Acetazolamide as a confirmatory diagnostic test for horn of the medulla and upper cervical horn evoked
migraine headaches, 362 by sagittal sinus stimulation in the cat, 355
Predictability of a migraine attack? An event-related Intracerebral arteries and gadolinium enhancement in
potential study, 363 migraine without aura, 363
Risk factors for a poor outcome of migraine without Sympathectomy induces C-fiber sprouting and mast
aura. A case-control study, 369 cell activation in rat dura mater, 370
Migraine associated with head trauma, 375 Parasympathetic stimulation induces plasma protein
Perception of health and quality of life of people with extravasation in rat dura mater, 370
frequent migraine attacks, 376 Red wine and vodka differ in their ability to reduce
stress, 378
The relevance of psychological factors in migraine, 377
Glyceryl trinitrate produces prolonged changes in
Clinical pattern and psychic sequelae of migraine, 378
cortical nitric oxide release in the anaesthetized cat,
Hemicrania with trigeminal neuralgia, 380
379
The hyperventilation migraine—a new clinical entity?,
Persistent pain and non-painful disagreeable sensation
381
after overdistension test stress the entity of “pain
Migraine and alexithymia: a Rorschach study, 383
memory” linked to the long-term potentiation in
Histamine inhalation is a specific but insensitive
migraine sufferers, 380
laboratory test for migraine, 550
Electroencephalogram and transcranial Doppler in
migraine—epidemiology
migraine with aura and in confusional migraine in
MIG ACCESS: a population-based, nationwide,
children, 388
comparative survey of access to care in migraine in
Autonomic nervous system function in migraineurs
France, 50 during headache-free period: a blood pressure and
Work-related disability: results from the American
heart rate variability study, 388
migraine study, 231 Discrimination between migraine patients and normals
Migraine without aura and migraine with aura are
based on the steady-state visual evoked potentials and
distinct clinical entities: study of 484 male and female
(SSVEPs): discriminant analysis and artificial neuronal
migraineurs from the general population, 239
network methods, 389
Incidence of severe migraine in the gazel cohort, 361
Migraine and oxidative stress involvement on platelet
A nosographic analysis of the migraine aura in a
responsiveness, 395
general population, 380 Platelet serotonin pathway in menstrual migraine, 427
migraine—genetics Visual system dysfunction in migraine: a review of
Familial hemiplegic migraine: a clinical comparison of clinical and psychophysical findings, 525
families linked and unlinked to chromosome 19, 153 migraine—pediatric
The family history of migraine. Direct versus indirect Is response to oral sumatriptan in childhood migraine
information, 156 different from adults, 358
Migraine without aura and migraine with aura are Headaches not fulfilling the criteria of migraine and
inherited disorders, 305 tension-type headache a follow-up study in children
Migrainous disorder and its relation to migraine and adolescents, 362
without aura and migraine with aura. A genetic Migraine with aura in childhood and adolescence—
epidemiological study, 362 clinical features of the aura, 376
The family history of migraine. Direct versus indirect Is abdominal migraine often environmentally
information, 392 determined?, 378
Analysis of 31 families with an apparently autosomal Electroencephalogram and transcranial Doppler in
dominant transmission of migraine with aura in the migraine with aura and in confusional migraine in
nuclear family, 393 children, 388
Point mutation (Arg506-Gln) of factor V in migraine Epidemiological study of headache in childhood, 401
with and without aura. A pilot study, 394 migraine—neurophysiology
Migraine association and linkage analyses of an MSPI Photic driving in migraine: correlations with clinical
polymorphism in the human 5HT2a receptor gene, 463 features, 246
migraine—pathogenesis migraine—therapy
Painful vein overdistension in migraine patients: no Pilot study of MK-462 in migraine, 113
relationship with serotoninergic parameters, 37 Prophylaxis of migraine with oral magnesium; results
viii Subject index CEPHALALGIA 16 (1996)
from a prospective, multi-center, placebo-controlled The aborption potential of electriptan (UK-116,044) and
and double-blind randomized study, 257 sumatriptan, 387
Risk factors for headache recurrence after sumatriptan: A dose-finding study of eletriptan (UK-116,044)
a study in 366 migraine patients, 264 (5-30 mg) for the acute treatment of migraine, 387
311C90 (Zolmitriptan), a novel centrally and peripheral 311C90 and sumatripan produce indistinguishable
acting oral 5-hydroxytryptamine-1D agonist: a CNS adverse event profiles, 389
comparison of its absorption during a migraine attack Screening of gliadin sensitivity in children suffering
and in a migraine-free period, 270 from migraine, 393
Serotonin syndrome complicating migraine Minimal interaction between 311C90, a novel
pharmacotherapy, 323 antimigraine compound, and oral pizotifen, 395
Long-term follow-up after flunarizine or nimodipine The combination of 311C90, a novel antimigraine
discontinuation in migraine patients, 337 compound, and oral propranolol in healthy subjects,
Pain control in migraine attacks: results from a double- 395
blind, randomized, within-patient, placebo-controlled The high efficacy of 311C90 in treating migraine
trial comparing diclofenac-K and ergotamine + headaches is maintained in patients using oral
caffeine, 359 contraceptives, 396
Dose-finding studies of rizatriptan (MK-462) in the Resolution without discomfort of analgesic drug abuse
acute treatment of migraine, 359 by suign 24 hours infusion of NMDA receptor
The effects of low doses of BMS-180048 compared with antagonist in migraine, 397
placebo in acute migraine, 360 Migraine prophylaxis with slow-release
Gabapentin in migraine prophylaxis, 367
dihydroergotamine, 398
A comparison of oral eletriptan (UK-116,044)
311C90 has no clinically significant effects on blood
(20-80 mg) and oral sumatriptan (100 mg) in the acute
pressure, 398
treatment of migraine, 368
Clinical effectiveness of verapamil in the management
The safety, tolerability and pharmacokinetics of oral
of migraine pain: a retrospective analysis, 398
eletriptan (UK-116,044) a potent and selective 5HT1D-
Oral 311C90 is effective in treatment of menstrual
like receptor agonist, 368
migraine, 400
Relief of migraine attack with N-methyl-D-aspartic
Confirmation of the long-term safety and efficacy of
acid receptor antagonist ketamine: a double-blind
oral 311C90 in the acute treatment of migraine:
comparison with placebo-theoretic implications, 372
demographic analysis from a study > 20,000 treated
Effects of ergotamine on myocardial blood flow—a pet
attacks, 400
study, 373
Headache induced by a nitric oxide donor
Sodium valproate in the prevention of migraine: case
(nitroglycerin) responds to sumatriptan. A human
studies on the effect of withdrawal of long term
model for development of migraine drugs, 412
therapy, 377
Alniditan in the acute treatment of migraine attacks: a
migraine—treatment
subcutaneous dose-finding study, 497
Side effects of ergotamine, 5
Post-marketing cohort study comparing the safety and Chest symptoms after sumatripan: a two year clinical
efficacy of flunarizine and propranolol in the practice review in 735 consecutive migraine patients,
prophylaxis of migraine, 328 554
Confirmation of the long-term safety of 311090 in the Magnesium in the prophylaxis of migraine—double-
acute oral treatment of migraine, 372 blind placebo controlled study, 436
Effects of orally administrered naltrexone in healthy Cyclandelate in the prophylaxis of migraine: a
randomized, parallel, double-blind study in
volunteers and migraine sufferers, 381
Nabumetone in migraine prophylaxis, 382 comparison with placebo and propranolol, 441
Efficacy of sumatriptan 50 mg/os in the migraine migraine with aura
attack. Open study on 50 patients, 383 Migraine with aura in childhood and adolescence—
Can sumatriptan be anxiogenic migraineurs, 384 clinical features of the aura, 376
Post-marketing clinical use- and misuse- of migraine without aura
sumatriptan in migraine patients: state of the art, 384 Migraine without aura and migraine with aura are
The safety, tolerability and pharmacokinetics of distinct clinical entities: study of 484 male and female
intravenous electriptan (UK-116,044), a new potent migraineurs from the general population, 239
and selective ’5HT 1D-line” receptor agonist, 385 migraine without aura—treatment
The use of sumatriptan in patients with concomitant Preventive drug use in migraine without aura, 383
epilepsy and migraine, 385 migrainous otalgia
In vitro pharmacology of electriptan (UK-116,044) a Migrainous otalgia—a new syndrome, 401
potent partial agonist at the ’’SHT-1D-like” receptor in morphine
the dog saphenous vein, 386 Differential sensitivity to morphine challenge in
Preclinical in vivo pharmacology of electriptan migraine sufferers and headache-exempt subjects,
(UK-116,044): a potent and selective partial agonist at 297
the ’5HT 1D-like” receptor, 386 MR imaging
The pharmacokinetics of eletriptan (UK-116,044) in rats Primary low cerebrospinal fluid pressure syndrome
and dogs, 387 with galactorrhea: findings at MR imaging, 124